The Effectiveness and Safety of Thunder Fire Moxibustion for Treating Allergic Rhinitis: A PRISMA Compliant Systematic Review and Meta-Analysis

الملخص EN

Background.

Allergic rhinitis (AR) is a noninfectious inflammatory disease caused by allergic individuals exposed to allergens.

Western medicine therapy for treating AR causes obvious adverse events, while thunder fire moxibustion (TFM) is known as a safe and effective treatment for AR.

Therefore, we conducted this meta-analysis to evaluate the effectiveness and safety of TFM for treating AR.

Methods.

PubMed, Web of Science, Embase, the Cochrane Library, CNKI, WanFang, VIP, and CBM from inception to April 5, 2020, were searched without any language restriction.

Reviewers identified studies, extracted data, and assessed the quality, independently.

The primary outcomes were the total effective rate and the TNSS.

The secondary outcomes included TNNSS, RQLQ, VAS, serum IgE, IgA, or IgG level, and adverse events.

Randomized controlled trials (RCTs) were collected; methodological quality was evaluated using the Cochrane risk of bias assessment tool (RoB), and the level of evidence was rated using the GRADE approach.

Meta-analysis was performed using the RevMan5.3.0 software.

Results.

A total of 18 RCTs were included, including 1600 patients.

The results of this meta-analysis showed a statistically significant effect in a total effective rate of T = TFM (RR = 1.07; 95% CI [1.03, 1.12]; P=0.45; I2 = 0%) and T = TFM + other treatments (RR = 1.18; 95% CI [1.11, 1.25]; P=0.03; I2 = 53%).

In addition, TFM intervention also showed significant difference in total symptom score (T = TFM + other treatments) (MD = −1.42; 95% CI [−1.55, −1.29]; P=0.03; I2 = 60%) in patients with AR.

Conclusion.

Existing evidence shows that TFM is safe and effective for AR.

Due to the universal low quality of the eligible trials and low evidence level, we should draw our conclusions with caution.

Therefore, clinical researchers should carry out more large-sample, multicentre, high-quality randomized controlled clinical trials in the future to verify the clinical efficacy of TFM in treating AR.